In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 371 to 380 of 387

TitleTypeExpected publication date
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Technology appraisal guidanceTBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Technology appraisal guidance
Vosoritide for treating achondroplasia in people 4 months and over ID6488Technology appraisal guidanceTBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]Highly specialised technologyTBC
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]Technology appraisal guidance
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Women's and reproductive health guidelinesNICE guidelineTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All